Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2025-08-10
Target enrollment:
Participant gender:
Summary
A number of studies suggest that the combination of PARP inhibitors and antiangiogenic agents
produce synergistic activities. Pamiparib is a small molecule inhibitor selectivity for both
PARP1 and PARP2. Surufatinib is a novel small-molecule inhibitor that simultaneously targets
tumor angiogenesis (via Vascular Endothelial Growth Factor Receptor [VEGFR]1, VEGFR 2, VEGFR3
and Fibroblast Growth Factor Receptor 1 [FGFR1]) and immune evasion (via Colony Stimulating
Factor 1 Receptor [CSF1R]). In this trial, we aimed to evaluate the efficacy, safety and
tolerability of pamiparib in combination with surufatinib in patients with platinum-resistant
ovarian cancer who received prior PARP inhibitors.